Monday, November 9, 2026
  • Login
Psychedelic Vantage | Covering Psychedelic Drug Development, Education, Research, and Investing
  • Home
  • Psychedelic News
  • Press Release
  • Investing
  • Education
  • Trip Reports
    • Phenethylamines
    • Tryptamines
    • Lysergamides
    • Dissociatives
  • Mental Health
No Result
View All Result
  • Home
  • Psychedelic News
  • Press Release
  • Investing
  • Education
  • Trip Reports
    • Phenethylamines
    • Tryptamines
    • Lysergamides
    • Dissociatives
  • Mental Health
No Result
View All Result
Psychedelic Vantage | Covering Psychedelic Drug Development, Education, Research, and Investing
No Result
View All Result

Numinus: Shaping a New Path to Wellness

Steve McCracken by Steve McCracken
February 14, 2024
in Investing
0
Numinus: Shaping a New Path to Wellness
314
VIEWS
Share on FacebookShare on Twitter

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is making major moves as one of the few clinic focused companies in the psychedelic sector. Numinus has been around since 2020, and has been successful in weathering the storm that has been the stock market over the past few years. While competitors like Field Trip were forced to shutter and sell, Numinus was able to cut costs while also acquiring more wellness clinics along the way through their acquisition of Novamind in 2022. Below we will take a deeper look into what this company is all about.

Who is Numinus Wellness?

Numinus Wellness started just like many others in the psychedelic sector at the beginning of the hype, doing their best to capitalize on the ensuing frenzy of money that was flowing in. They were hoping to study a psilocybin-based tea to aid in psilocybin assisted therapy. They have since shuttered their biosciences division to focus more on providing in-clinic care and training practitioners. Their focus is high quality education while also being able to supply the high demand. The company claims this training is scalable, with over 700 learners enrolled to date. They currently provide numerous services at their clinics, to include: Psychiatric services with medicine management, traditional therapy/counseling, virtual, SPRAVATO®, Ketamine-assisted therapy, Transcranial magnetic stimulation (TMS), and MDMA- and Psilocybin-assisted therapy (for SAP-approved clients). They also have a partnership with the Multidisciplinary Association for Psychedelic Studies (MAPS), to support psychedelic experiential opportunities for practitioners as part of a clinical study. If approved by Health Canada, the clinical trial would enable practitioners interested in MDMA-assisted therapy the ability to experience and observe MDMA sessions to further their understanding of psychedelic-assisted therapy. Numinus also claims to have expertise with insurance coverage which will be a huge asset as regulations change and policies shift in the coming years.

How many clinics?

When Numinus acquired Novamind in 2022 it had 13 wellness clinics, 4 clinical research facilities, and a psychedelics research facility. In September 2023, Numinus shuttered its biosciences division as well as consolidating its wellness clinics, leaving them with 9 remaining. This was in an effort to cut costs amidst a challenging financial environment for the entire market. We will discuss financials in the next paragraph.

The nitty gritty.

Many companies in this sector have the luxury of seeming amazing at the surface due to the potential of psychedelics.  Unfortunately, some companies have shown to be quite ugly when we look underneath the hood. Luckily for us it seems Numinus Wellness is doing what they can to point the ship in the right direction financially. Based on financials Numinus reported a gross profit of $2.15 million expenses, down $226,643 from 2022. This shows me the shuttering of the biosciences and clinic consolidation was a smart move due to the massive decrease in expenses with only a slight dip to gross profit. Next, we look at expenses for 2023 totaling $6.31 million, down a staggering $2,778,135 from the same time in 2022. All of this resulted in a loss of $4.41 million, down from $6.72 million in 2022. As of November 30, 2023 Numinus had $4.7 million cash on hand. Then on Feb 1st, 2024 Numinus announced a $6 million bought deal public offering. Seeing as Numinus is burning through roughly $ 4 million in cash per quarter they should be able to continue as normal with no need for financing for roughly 5-6 months, not accounting for any revenue.

What’s next?

Numinus Wellness seems to have learned from the competition. They shifted when they needed to and adjusted their spending, allowing them to continue to be a leader in the clinical area of psychedelic therapy. Will they be able to scale their therapy training as expected? Time will tell. It will be a difficult task continuing to streamline operations, cut costs, and produce revenue. One thing is for sure though, if Numinus continues to operate as efficiently as they have been, we can expect to see them thrive in the future.

Disclaimer: The content provided is for informational purposes only and should not be considered as financial advice. We are not financial advisors, and the information presented is not a substitute for professional consultation. While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or reliability of the information. Any reliance on this information is at your own risk, and we are not liable for any loss or damage arising from its use. It is recommended to consult with a qualified financial professional for specific advice. We reserve the right to modify, update, or remove content without notice

Tags: biotechNuminusPsychedelic biotechpsychedelic investingpsychedelic scienceshroom stocks
Previous Post

Nevada Contemplates Legalizing Psychedelic Medicines

Next Post

A Trip Into the Infinite Self

Next Post
A Trip Into the Infinite Self

A Trip Into the Infinite Self

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • About
  • Disclaimer
  • Advertise
  • Privacy Policy
  • Contact Us
Email General@psychedelicvantage.com

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Please wait...

Subscribe to our weekly newsletter!

Subscribe below to gain exclusive access to captivating articles and receive notifications whenever a new article is published!
SIGN UP FOR NEWSLETTER NOW
No Result
View All Result
  • Home
  • Psychedelic News
  • Press Release
  • Investing
  • Education
  • Trip Reports
    • Phenethylamines
    • Tryptamines
    • Lysergamides
    • Dissociatives
  • Mental Health

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.